5-Year Outcomes of a Phase I Dose Escalation Study Using Stereotactic Body Radiosurgery for Patients with Low and Intermediate Risk Prostate Cancer

To report toxicity outcomes, PSA relapse, and cumulative incidence-post-treatment biopsy results among patients treated on a prospective dose escalation study using ultra-hypofractionated stereotactic body radiotherapy (SBRT) for patients with low/intermediate risk prostate cancer.

http://bit.ly/2CN0bJv